Articles written by Scilex Holding Company - Benzinga

Semnur Pharmaceuticals, Inc., A Wholly Owned Subsidiary Of Scilex Holding Company, Announces Today The Filing Of A Registration Statement On Form S-4 by Denali Capital Acquisition Corp. With The Securities And Exchange Commission Relating To The Previously Announced Proposed Business Combination Between Semnur And Denali

Sponsored

Scilex Holding Company Announces Signing Of A $50 Million Registered Convertible Financing To Refinance And Restructure Existing Debt & Further Strengthens Financial Profile

Sponsored

Scilex Holding Company Announces That The U.S. Bankruptcy Court Has Extended The Lockup Period On Shares Of Scilex Dividend Stock Previously Distributed By Sorrento To Its Stockholders As A Dividend To January 31, 2025

Sponsored

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended July 31, 2024

Sponsored

Scilex Holding Company Announces Publication of Its Inaugural Sustainability Report

Sponsored

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination

Sponsored

Scilex Holding Company Partners With New National Distributor, Endeavor Distribution LLC.

Sponsored

Scilex Holding Company Announces Publication In PAIN Journal Regarding Phase 3 Results Of The Pivotal Registration Trial Of SP-102 (SEMDEXA™) In Lumbosacral Radicular Pain (Sciatica)

Sponsored

Scilex Holding Company Announces That Many National Pharmacy Chains And Independent Pharmacies Have Begun Stocking GLOPERBA®

Sponsored

Scilex Holding Company Announces Stocking Of GLOPERBA® Is Underway In All Of The Wholesalers With Which Scilex Has Stocking Arrangements Throughout The U.S.

Sponsored

Scilex Holding Company Sends Letters To The U.S. Securities And Exchange Commission And Financial Industry Regulatory Authority Regarding Illegal Market Manipulation Of The Common Stock Of Scilex Holding Company

Sponsored

Scilex Holding Company Announces It Has Been Added To The MSCI Global Microcap Index

Sponsored

Scilex Holding Company Announces Final Court Approval Of A Settlement Agreement With Takeda Pharmaceuticals To Resolve The Paragraph IV Patent Infringement Lawsuit Relating To Scilex's Intent To Expand The Label For Its FDA-Approved Liquid Colchicine Product, Gloperba®

Sponsored

Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada

Sponsored

Scilex Holding Announces Issuance Of Halal Certification For Its ZTlido® Product By Circle H International, Inc.

Sponsored

Scilex Holding Company's Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered Into A Definitive Mutual Release And Settlement Agreement With Virpax Pharmaceuticals, Inc. Relating To The Previously Announced Term Sheet With Virpax In Respect Of Such Release And Settlement

Sponsored

Scilex Holding Company Sets Launch Price Of $595 Per 150ml Bottle Of Gloperba®, Its First And Only Liquid Oral Version Of The Anti-Gout Medicine Colchicine Indicated For The Prophylaxis Of Painful Gout Flares In Adults; Expected Plans To Launch In The First Half Of 2024

Sponsored

Scilex Holding Company Announces That The Official Committee Of Unsecured Creditors Of Sorrento Therapeutics, Inc., Has Filed A Motion With The U.S. Bankruptcy Court To Extend The Lockup Period On Shares Of Scilex Stock Previously Distributed By Sorrento To Its Stockholders As A Dividend From March 31, 2024 To September 30, 2024

Sponsored

Scilex Holding Company Announces $10 Million Bought Deal Offering

Sponsored

Scilex Holding Company Announces Major Initiative With A Leading National Pharmacy Chain To Stock GLOPERBA® In Most Of Their Stores Throughout the U.S.

Sponsored